1FDA, HHS. Drug labeling, orally ingested over-the-counter drug produces containing calcium, magnesium,and potassium. Final rule Fed Regist. 2004; 691577:13725-13735.
2Wakefield J. FDA etes pharmacogenomics data. Environ Health Perspect. 2004; 112 (4): A217.
3Meadows M. The FDA and the fight against terrorism.FDA Consum. 2004; 38 (1): 202-207.
4FDA, HHS. Medical devices, hematology and pathology devices; classification of the Factor V leiden DNA mutation detection systems devices. Final rule. Fed Regist.2004; 69 (51): 12271-12273.
5Carpenter DP. The political economy of FDA drug review: processing, politics, and lesons for policy. Health Aff (Millwood). 2004; 23 (1): 2000-2007.
6FDA, HHS. Human cells, tissues, and cellular and tissue-based products ; establishment registration and listing. Interim final rule; opportunity for public comment. Fed Regist. 2004; 69 (17): 3823-3826.
7FDA, HHS. Biological products; bacterial vaccines and toxoids ; implementation of efficacy review. Final rule and final order. Fed regist. 2004; 69 (2): 255-267.
8Moynihan R. FDA advisory panel calls for suicide warnings over new antidepressants. BMJ. 2004; 328 (7435):303.
9Schmidt E, Wong R. 'New' FDA delivers in 2003. Nat Rev Drug Discov. 2003; 2 (12): 941-942.
10Savage DR. VS Food and Drug Administration. FDA guidance on pharmacogenomics data submission. Nat Rev Drug Discov. 2003; 2 (12): 937-938.
